Designing two-in-one antibodies.

Abstract:

:Evaluation of: Bostrom J, Shang-Fan Y, Kan D et al.: Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009). The longstanding held notion that one antibody equals one antigen and, hence, one function has been challenged in recent years. Improved technology in antibody production, especially the accumulation of sequence data of immunoglobulin genes and the advent of PCR have made it possible to clone antibody gene repertoires. The current paper provides further challenge to the notion of one antibody = one antigen by developing 'two-in-one' antibodies with an antigen-binding site that binds two distinct proteins with high affinity. A therapeutic variant antibody of Herceptin (Genentech, CA, USA) was isolated that binds the human EGF receptor (HER)2 and also to VEGF. This development may represent a breakthrough discovery and may have significant implications in the therapy of malignant, infectious, allergic and autoimmune disorders.

journal_name

Immunotherapy

journal_title

Immunotherapy

authors

Valladares IG,Espinoza LR

doi

10.2217/imt.09.39

subject

Has Abstract

pub_date

2009-09-01 00:00:00

pages

749-51

issue

5

eissn

1750-743X

issn

1750-7448

journal_volume

1

pub_type

评论,杂志文章
  • Restricted mean survival time as outcome measure in advanced urothelial bladder cancer: analysis of 4 clinical studies.

    abstract::Background: The purpose of this study was to assess the effectiveness of immune checkpoint inhibitors (ICIs) in advanced urothelial carcinoma. Materials & methods: We selected seven cohorts of patients published in four clinical trials. The restricted mean survival time (RMST) was used to analyze survival curves, perf...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0160

    authors: Rivano M,Cancanelli L,Spazio LD,Chiumente M,Mengato D,Messori A

    更新日期:2021-02-01 00:00:00

  • Phacilitate Barcelona active immunotherapeutics forum. 11-13 May 2011, Barcelona, Spain.

    abstract::The era of active immunotherapy has now been successfully ushered into the clinical realm of advanced prostate cancer. The successful clinical trial development and US FDA approval of sipuleucel-T (Provenge®) has revamped the therapeutic paradigm for advanced prostate cancer. Nonetheless, physician and patient educati...

    journal_title:Immunotherapy

    pub_type: 总体

    doi:10.2217/imt.11.90

    authors: Shore ND

    更新日期:2011-08-01 00:00:00

  • Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia.

    abstract::Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration. Its incidence is rare and rarer still is its ability to transform to a B-cell lymphoma, particularly the aggressive diffuse large B-cell lymphoma, which ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0027

    authors: Okolo ON,Johnson AC,Yun S,Arnold SJ,Anwer F

    更新日期:2017-08-01 00:00:00

  • Depletion of Tregs in vivo: a promising approach to enhance antitumor immunity without autoimmunity.

    abstract::Evaluation of: Rech AJ, Mick R, Martin S et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patents. Sci. Transl. Med. 4(134), 134ra62 (2012). Tregs are involved in the maintenance of immunological self-tolerance. Recent studies have revealed that Tregs ...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.12.116

    authors: Morita R,Hirohashi Y,Sato N

    更新日期:2012-11-01 00:00:00

  • Heat-shock proteins as endogenous ligands building a bridge between innate and adaptive immunity.

    abstract::There has been growing evidence that heat-shock protein (HSP) functions as an endogenous immunomodulator for innate and adaptive immune responses. Since HSPs inherently act as chaperones within cells, passive release (e.g., by cell necrosis) and active release (including release by secretion in the form of an exosome)...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.12.75

    authors: Tamura Y,Torigoe T,Kukita K,Saito K,Okuya K,Kutomi G,Hirata K,Sato N

    更新日期:2012-08-01 00:00:00

  • Immunotherapy of chronic myeloid leukemia: present state and future prospects.

    abstract::In spite of the considerable successes that have been achieved in the treatment of chronic myeloid leukemia (CML), cure for the disease can only be obtained by the present means in a rather small minority of patients. During the past decade, considerable progress has been made in the understanding of the immunology of...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.2

    authors: Vonka V

    更新日期:2010-03-01 00:00:00

  • PROSTVAC® targeted immunotherapy candidate for prostate cancer.

    abstract::Targeted immunotherapies represent a valid strategy for the treatment of metastatic castrate-resistant prostate cancer. A randomized, double-blind, Phase II clinical trial of PROSTVAC® demonstrated a statistically significant improvement in overall survival and a large, global, Phase III trial with overall survival as...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.13.176

    authors: Shore ND

    更新日期:2014-01-01 00:00:00

  • Safe administration of anti-PD-1 immunotherapy in a patient with pre-existing primary biliary cholangitis.

    abstract::A 63-year-old female presented with cholestatic liver function tests in November 2016. Screening tests were negative for other causes and liver biopsy revealed primary biliary cholangitis (PBC) with autoimmune hepatitis (AIH) overlap. Ursodeoxycholic acid and azathioprine was initiated. In September 2018 she was diagn...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2019-0184

    authors: Bhave P,Pham A,Gordon A,Moore M

    更新日期:2020-05-01 00:00:00

  • So slow, so fast, a case of nivolumab-induced hypothyroidism with subsequent rhabdomyolysis.

    abstract::Background: Immunotherapy has revolutionized the treatment of cancer, but this has not come without a cost. Although immune checkpoint inhibitors are less toxic than conventional chemotherapy, they are associated with more frequent autoimmune side effects. Case presentation: We report a case of a patient with metastat...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0053

    authors: Abushalha K,Abulaimoun S,Silberstein PT

    更新日期:2020-06-01 00:00:00

  • Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?

    abstract::Evaluation of: Pesce B, Soto L, Sabugo F et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin. Exp. Immunol. 171, 237-242 (2012). Clinical trials of a humanized anti-IL-6 receptor antibody, tocilizumab (TCZ), proved...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.47

    authors: Tanaka T

    更新日期:2013-07-01 00:00:00

  • FOCIS goes south: advances in translational and clinical immunology.

    abstract::FOCIS goes South: Advances in Translational and Clinical Immunology was the first Federation of Clinical Immunology Societies (FOCIS) ( www.focisnet.org ) meeting held in Latin America (May 15-17, 2017, Santiago de Chile, Chile). The meeting was organized as a 3-day workshop and was fostered by the Millennium Institut...

    journal_title:Immunotherapy

    pub_type:

    doi:10.2217/imt-2017-0079

    authors: Kalergis AM,Anegon I,González PA

    更新日期:2017-09-01 00:00:00

  • Antibody-targeted nanoparticles for cancer therapy.

    abstract::In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, i...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.5

    authors: Fay F,Scott CJ

    更新日期:2011-03-01 00:00:00

  • Safety evaluation of a multiallergen immunotherapy treatment in polyallergic patients. APOLO observational study.

    abstract::Aim: Assessment of safety, tolerability and changes in global clinical impression with an multiallergen immunotherapy treatment without dilutional effect in polyallergic patients. Patients & methods: This observational prospective study included patients with allergic rhinitis-rhinoconjunctivitis with or without asthm...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2019-0187

    authors: Alba P,Moreno V,Arias-Irigoyen J,Antón M,Parra A,Gómez-Fernández MC,Madariaga B,Martínez A,Begoña L

    更新日期:2020-01-01 00:00:00

  • Jacalin regulates IgA production by peripheral blood mononuclear cells.

    abstract:AIMS:In IgA nephropathy, circulating immune complexes containing IgA1 are deposited on the glomerular mesangium, causing mesangial cell proliferation and acceleration of extracellular matrix production. The suppressive effect of jacalin, a galactose-binding lectin, on IgA production in vitro was determined. MATERIALS ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.125

    authors: Miyamoto K,Chiba T,Shinohara N,Nagata Y,Asakawa N,Kato S,Mizutani N,Murata T,Nomura S,Horiuchi T

    更新日期:2012-12-01 00:00:00

  • γδ T cells as a potential tool in colon cancer immunotherapy.

    abstract::γδ T cells are capable of recognizing tumor cells and exert potent cellular cytotoxicity against a large range of tumors, including colon cancer. However, tumors utilize numerous strategies to escape recognition or killing by patrolling γδ T cells, such a downregulation of NKG2D ligands, MICA/B and ULBPs. Therefore, t...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.59

    authors: Ramutton T,Buccheri S,Dieli F,Todaro M,Stassi G,Meraviglia S

    更新日期:2014-01-01 00:00:00

  • Cancer testis antigens as immunogenic and oncogenic targets in breast cancer.

    abstract::Breast cancer cells frequently express tumor-associated antigens that can elicit immune responses to eradicate cancer. Cancer-testis antigens (CTAs) are a group of tumor-associated antigens that might serve as ideal targets for cancer immunotherapy because of their cancer-restricted expression and robust immunogenicit...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0179

    authors: Mahmoud AM

    更新日期:2018-07-01 00:00:00

  • Antibody-based immunotherapy of solid cancers: progress and possibilities.

    abstract::Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host-tumor interaction has defined a new range of targets fo...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.57

    authors: Nicodemus CF

    更新日期:2015-01-01 00:00:00

  • Timely blockade of ICAM-1.LFA-1 interaction prevents disease onset in a mouse model of emphysema.

    abstract:AIM:It is becoming apparent that emphysema is partly driven by self-reactive T cells inducing inflammatory damage. Thus, T cells become targets for therapy similar to other autoimmune diseases. Costimulatory blockade therapy targets disease-specific T cells, rendering them ineffective by blocking a necessary costimulat...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.15.31

    authors: Newton AH,Danahy DB,Chan MA,Benedict SH

    更新日期:2015-01-01 00:00:00

  • Tumor-associated macrophages: implications in cancer immunotherapy.

    abstract::Tumor-associated macrophages (TAMs), representing most of the leukocyte population in solid tumors, demonstrate great phenotypic heterogeneity and diverse functional capabilities under the influence of the local tumor microenvironment. These anti-inflammatory and protumorigenic macrophages modulate the local microenvi...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2016-0135

    authors: Petty AJ,Yang Y

    更新日期:2017-03-01 00:00:00

  • PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis.

    abstract:AIM:This meta-analysis aims at assessing the correlation of PD-L1 levels and response PD-1/PD-L1 inhibitors in advanced malignant melanoma. METHODS:Eligible studies included those evaluating PD-1/PD-L1 inhibitors in advanced melanoma and correlating the outcomes to PD-L1 levels. RESULTS:After preclusion of ineligible...

    journal_title:Immunotherapy

    pub_type: 杂志文章,meta分析

    doi:10.2217/imt-2016-0025

    authors: Abdel-Rahman O

    更新日期:2016-09-01 00:00:00

  • Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory.

    abstract::Brain tumors present unique therapeutic challenges and they include glioblastoma (GBM) and metastases from cancers of other organs. Current treatment options are limited and include surgical resection, radiation therapy, laser interstitial thermal therapy and chemotherapy. Although much research has been done on the d...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2019-0023

    authors: Liu Y,Chongsathidkiet P,Crawford BM,Odion R,Dechant CA,Kemeny HR,Cui X,Maccarini PF,Lascola CD,Fecci PE,Vo-Dinh T

    更新日期:2019-10-01 00:00:00

  • Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema.

    abstract::Hereditary angioedema (HAE) is a relatively rare autosomal dominant disorder that is typically characterized by recurrent episodes of edema in various body locations. It is most commonly caused by an inherited deficiency of functionally active C1 esterase inhibitor (C1-INH). Replacement therapy with a human plasma-der...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.33

    authors: Bork K

    更新日期:2014-01-01 00:00:00

  • Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals.

    abstract:AIMS:A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. PATIENTS & METHODS:Monocytes o...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0165

    authors: da Silva LT,da Silva WC,de Almeida A,da Silva Reis D,Santillo BT,Rigato PO,da Silva Duarte AJ,Oshiro TM

    更新日期:2018-08-01 00:00:00

  • Safety and effectiveness of a microcrystalline tyrosine-associated mite extract immunotherapy for allergic rhinitis.

    abstract::Aim: To assess the safety and effectiveness of an allergen immunotherapy (AIT) with a microcrystalline tyrosine-associated mite allergoid in real-world patients with allergic rhinitis (AR). Materials & methods: Retrospective, multicenter study assessing the safety of AIT in patients aged 5 to 65 years with AR, with or...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0194

    authors: Sala-Cunill A,Pérez-Formoso JL,Torán-Barona C,Almeida-Sánchez ZM,Álvarez-Fernández JA,García-Núñez I,Linana-Santafé JJ,Martínez-Tadeo JA,Boronat-Barado A,Justicia JL

    更新日期:2020-09-01 00:00:00

  • Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma.

    abstract::Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. I...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.39

    authors: Muccioli M,Longstaff C,Benencia F

    更新日期:2012-05-01 00:00:00

  • Conference scene: progress with promising human antibodies.

    abstract::Antibodies and antibody-based therapeutics have become big business, with annual sales over US$50 billion, accounting for >6% of worldwide pharmaceutical revenues. Ten molecules have blockbuster status (>US$1 billion), with six generating more than US$6 billion in sales. In excess of 300 products based on this rapidly...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.5

    authors: Larrick JW

    更新日期:2012-03-01 00:00:00

  • Intraperitoneal radioimmunotherapy: Auger electron emitters for solid tumors.

    abstract::Evaluation of: Boudousq V, Ricaud S, Garambois V et al.: Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing (125)I-labeled monoclonal antibodies. J. Nucl. Med. 51, 1748-1755 (2010). Mesothelioma, pseudomyxoma peritonei, ovarian and colon cancers, and s...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.11.11

    authors: Baranowska-Kortylewicz J

    更新日期:2011-04-01 00:00:00

  • Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.

    abstract::Taking advantage of the cellular immune system is the mainstay of the adoptive cell therapy, to induce recognition and destruction of cancer cells. The impressive demonstration of this principle is chimeric antigen receptor-modified T (CAR-T)-cell therapy, which had a major impact on treating relapsed and refractory h...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0181

    authors: El-Khazragy N,Ghozy S,Emad P,Mourad M,Razza D,Farouk YK,Mohamed NA,Ahmed MK,Youssef T,Bahnasawy YM,Elmasery S

    更新日期:2020-12-01 00:00:00

  • Role of myeloid-derived suppressor cells in tumor immunotherapy.

    abstract::Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that infiltrate human and experimental tumors and strongly inhibit anticancer immune response directly or by inducing regulatory T-lymphocyte activity. Consequently, MDSCs are important actors of cancer-induced immune tolerance and a major obstacle to...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.154

    authors: Martin F,Apetoh L,Ghiringhelli F

    更新日期:2012-01-01 00:00:00

  • Efficacy of a 3-year course of sublingual immunotherapy for mite-induced allergic rhinitis with a 3-year follow-up.

    abstract::Aim: To evaluate the long-term efficacy of sublingual immunotherapy (SLIT) in treating mite-sensitized allergic rhinitis (AR). Materials & methods: 150 AR children were randomly divided into SLIT and pharmacotherapy (PT) groups, receiving a 3-year course of SLIT along with PT or PT only. Results: The symptom and medic...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0006

    authors: Chen WB,Shen XF,Li Q,Zhou WC,Cheng L

    更新日期:2020-08-01 00:00:00